Novocure’s Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/29/2026

1. V
2. PYPL
3. KLAC
4. SPY
5. F
6. STX
7. CSGP
8. BE
9. SWKS
10. META

Go back to Novocure’s Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer
(NASDAQ: NVCR) Delayed: 15.20 -1.11 (6.81%)
Previous Close $16.31    52 Week High $28.95 
Open $16.06    52 Week Low $5.95 
Day High $16.39    P/E N/A 
Day Low $15.12    EPS $0.00 
Volume 1,506,697